Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Queensland Health
Farmers Insurance
Express Scripts
UBS
Novartis
Federal Trade Commission
Teva
Dow

Generated: October 18, 2017

DrugPatentWatch Database Preview

Allergan Sales Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN SALES LLC, and when can generic versions of ALLERGAN SALES LLC drugs launch?

ALLERGAN SALES LLC has thirty approved drugs.

There are twenty US patents protecting ALLERGAN SALES LLC drugs.

There are two hundred and twenty-seven patent family members on ALLERGAN SALES LLC drugs in thirty countries and fifty-eight supplementary protection certificates in twelve countries.

Summary for Applicant: Allergan Sales Llc

International Patents:227
US Patents:20
Tradenames:27
Ingredients:21
NDAs:30
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-001Jan 14, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
FIORINAL
aspirin; butalbital; caffeine
TABLET;ORAL017534-003Apr 16, 1986DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-002Jan 14, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Allergan Sales Llc
GELNIQUE
oxybutynin chloride
GEL;TRANSDERMAL022204-001Jan 27, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
DILACOR XR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020092-003May 29, 1992DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
NORINYL 1+35 28-DAY
ethinyl estradiol; norethindrone
TABLET;ORAL-28017565-002Approved Prior to Jan 1, 1982ABRXNoNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
SAVELLA
milnacipran hydrochloride
TABLET;ORAL022256-003Jan 14, 2009ABRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-004Apr 5, 2002BXRXNoNo► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-011Jul 9, 2012RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan Sales Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
TRELSTAR
triptorelin pamoate
INJECTABLE;INTRAMUSCULAR020715-001Jun 15, 2000► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-003Dec 20, 1996► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-002Dec 20, 1996► Subscribe► Subscribe
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-001Sep 29, 1995► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-001Jul 3, 1996► Subscribe► Subscribe
Allergan Sales Llc
DILACOR XR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020092-003May 29, 1992► Subscribe► Subscribe
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-001Sep 29, 1995► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-004Apr 5, 2002► Subscribe► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN SALES LLC drugs

Drugname Dosage Strength Tradename Submissiondate
oxybutynin chloride
Gel10%
GELNIQUE
6/19/2014
milnacipran hydrochloride
Tablets12.5 mg, 25 mg, 50 mg, and 100 mg
SAVELLA
1/14/2013
silodosin
Capsules4 mg and 8 mg
RAPAFLO
10/9/2012
oxybutynin
Transdermal System Extended-re3.9 mg/24 hrs
OXYTROL
8/19/2008

Non-Orange Book Patents for Allergan Sales Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,404,965Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
7,335,379Transdermal pharmaceutical formulation for minimizing skin residues► Subscribe
8,652,491Transdermal compositions for anticholinergic agents► Subscribe
6,635,675 Method of treating chronic fatigue syndrome► Subscribe
8,980,290Transdermal compositions for anticholinergic agents► Subscribe
7,214,381Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
7,470,433Formulations for transdermal or transmucosal application► Subscribe
7,915,246Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain► Subscribe
7,387,788Pharmaceutical compositions of nicotine and methods of use thereof► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Sales Llc Drugs

Country Document Number Estimated Expiration
Hong Kong1103639► Subscribe
Germany60143477► Subscribe
New Zealand588109► Subscribe
Israel168327► Subscribe
Denmark1565136► Subscribe
South Korea100856523► Subscribe
Japan2015134811► Subscribe
Austria552856► Subscribe
Malaysia145340► Subscribe
World Intellectual Property Organization (WIPO)2004045636► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Sales Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
09/012Ireland► SubscribePRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
C/GB10/031United Kingdom► SubscribePRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
2009Austria► SubscribePRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C/GB09/024United Kingdom► SubscribePRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Accenture
Express Scripts
Cantor Fitzgerald
Farmers Insurance
Novartis
Dow
Deloitte
Harvard Business School
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot